In the first of a two part series, hear directly from Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, who led the much of the development and regulatory work. He recounts the challenges and triumphs of navigating the process from a promising discovery to a regulatory success for rare disease patients.

CLINUVEL’s Regulatory Affairs Manager (Cosmetics), Alice Lynn, is back in this episode to demystify the labels on cosmetic products and explore how brands determine shelf life and efficacy claims. Tune in to learn what it takes to get a safe, effective, and innovative cosmetic from the lab to your vanity table.

In this podcast episode, CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joined Sarah Mawson to unpack SPF: what is it? How do we test for it? And why some labels may not be what they seem.

In this podcast episode, Dr Emilie Rodenburger, Director, Global Clinical Affairs at CLINUVEL, elaborates on the scientific basis for using afamelanotide in vitiligo, and provides insights on key learnings from the program to date.

Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...

Those of us working from offices, or our own homes, aren’t expecting danger pay.  However, what about those who have jobs that heighten the risk of getting skin...

Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...

Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...

Following the release of CLINUVEL’s FY2026 Annual Results, CEO Dr Philippe Wolgen sits down with financial commentator and business journalist, Susannah Streeter, to unpack the Company’s considerations whether to fully list on Nasdaq and delist from the ASX.

CLINUVEL hosted an investor webinar following the release of its FY2026 results on 27 August 2026. Mr Malcolm Bull, Head of Investor Relations and Australia Operations, is joined by Mr Peter Vaughan, Chief Financial Officer; Dr Philippe Wolgen, Managing Director; and Dr Emilie Rodenburger to review the results and discuss the Company’s expansion plan and pipeline.

CLINUVEL (ASX:CUV) hosted an investor webinar to review the half year results and operational highlights for the six months ended on 31 December 2025.

CLINUVEL’s 2025 Annual General Meeting was held on 17 October 2025. Watch the recording from the event.